Oxazole hydroxamic acid derivatives and use thereof
Provided are an oxazole hydroxamic acid derivatives and pharmaceutically useful salt thereof as a histone deacetylase inhibitor. The oxazole hydroxamic acid derivative and pharmaceutically useful salt thereof, prepared in accordance with the present invention, can treat and/or prevent various cancers and inflammatory diseases caused by histone deacetylase.
1. An oxazole hydroxamic acid derivative selected from the group consisting of 7-(5-(4-methoxy-phenyl)-4-phenyl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(2-methoxy-phenyl)-4-phenyl-oxazol-2-yl-heptanoic acid hydroxyamide, 7-[5-(3-methoxy-phenyl)-4-phenyl-oxazol-2-yl-heptanoic acid hydroxyamide, 7-[5-(2-fluoro-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[5-(3-fluoro-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-(4-phenyl-5-p-tolyl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(4-ethoxy-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[5-(4-fluoro-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4,5-bis-(4-methoxy-phenyl)-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(2-methoxy-phenyl)-5-(4-methoxy-phenyl)-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[5-(4-dimethylamino-phenyl)-4-phenyl-oxazol-2-yl]-haptanoic acid hydroxyamide, acid hydroxyamide, 7-[4-(4-methoxy-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(4-dimethylamino-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(4-fluoro-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(3-fluoro-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-(4-phenyl-5-pyridin-4-yl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(4-methoxy-phenyl)-4-pyridin-4-yl-oxazol-2-yl)heptanoic acid hydroxyamide, 7-[5-(4-ethoxy-phenyl)-4-pyridin yl-oxazol-2-yl)-heptanoic acid hydroxyamide and 7-[5-(4-hydroxy-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide; or a pharmaceutically useful salt thereof.
2. A pharmaceutical composition comprising an oxazole hydroxamic acid derivative selected from the group consisting of 7-(5-(4-methoxy-phenyl)-4-phenyl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(2-methoxy-phenyl)-4-phenyl-oxazol-2-yl-heptanoic acid hydroxyamide, 7-[5-(3-methoxy-phenyl)-4-phenyl-oxazol-2-yl-heptanoic acid hydroxyamide, 7-[5-(2-fluoro-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[5-(3-fluoro-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-(4-phenyl-5-p-tolyl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(4-ethoxy-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[5-(4-fluoro-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4,5-bis-(4-methoxy-phenyl)-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(2-methoxy-phenyl)-5-(4-methoxy-phenyl)-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[5-(4-dimethylamino-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(4-methoxy-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(4-dimethylamino-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(4-fluoro-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(3-fluoro-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-(4-phenyl-5-pyridin-4-yl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(4-methoxy-phenyl)-4-pyridin-4-yl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(4-ethoxy-phenyl)-4-pyridin-4-yl-oxazol-2-yl)-heptanoic acid hydroxyamide and 7-[5-(4-hydroxy-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide.
3. A histone decarboxylase inhibitor comprising an oxazole hydroxamic acid derivative selected from the group consisting of 7-(5-(4-methoxy-phenyl)-4-phenyl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(2-methoxy-phenyl)-4-phenyl-oxazol-2-yl-heptanoic acid hydroxyamide, 7-[5-(3-methoxy-phenyl)-4-phenyl-oxazol-2-yl-heptanoic acid hydroxyamide, 7-[5-(2-fluoro-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[5-(3-fluoro-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-(4-phenyl-5-p-tolyl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(4-ethoxy-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[5-(4-fluoro-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4,5-bis-(4-methoxy-phenyl)-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(2-methoxy-phenyl)-5-(4-methoxy-phenyl)-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[5-(4-dimethylamino-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(4-methoxy-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(4-dimethylamino-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(4-fluoro-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-[4-(3-fluoro-phenyl)-5-pyridin-3-yl-oxazol-2-yl]-heptanoic acid hydroxyamide, 7-(4-phenyl-5-pyridin-4-yl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(4-methoxy-phenyl)-4-pyridin-4-yl-oxazol-2-yl)-heptanoic acid hydroxyamide, 7-[5-(4-ethoxy-phenyl)-4-pyridin-4-yl-oxazol-2-yl)-heptanoic acid hydroxyamide and 7-[5-(4-hydroxy-phenyl)-4-phenyl-oxazol-2-yl]-heptanoic acid hydroxyamide.
4. The inhibitor according to claim 3 , wherein the inhibitor is an anticancer agent for cervical cancer, colon cancer, breast cancer, blood cancer and prostate cancer or an anti-inflammatory agent.